Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
Mallinckrodt
McKesson
Harvard Business School

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR TAFAMIDIS MEGLUMINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tafamidis Meglumine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01435655 ↗ The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed Pfizer Phase 3 2011-11-01 Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
NCT01994889 ↗ Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Completed Pfizer Phase 3 2013-12-09 This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
NCT02791230 ↗ Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy Active, not recruiting Pfizer Phase 3 2016-06-13 Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tafamidis Meglumine

Condition Name

Condition Name for Tafamidis Meglumine
Intervention Trials
Healthy 3
Transthyretin (TTR) Amyloid Cardiomyopathy 2
Healthy Volunteers 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tafamidis Meglumine
Intervention Trials
Amyloidosis 4
Amyloid Neuropathies 2
Cardiomyopathies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tafamidis Meglumine

Trials by Country

Trials by Country for Tafamidis Meglumine
Location Trials
United States 39
Japan 8
Canada 6
China 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tafamidis Meglumine
Location Trials
Utah 2
Massachusetts 2
Alabama 2
California 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tafamidis Meglumine

Clinical Trial Phase

Clinical Trial Phase for Tafamidis Meglumine
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tafamidis Meglumine
Clinical Trial Phase Trials
Completed 6
Recruiting 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tafamidis Meglumine

Sponsor Name

Sponsor Name for Tafamidis Meglumine
Sponsor Trials
Pfizer 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tafamidis Meglumine
Sponsor Trials
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Dow
Merck
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.